NotableEligibility criteria shortened, about 23 words
Trial sites expanded: 0 → 5 locations
Secondary endpoints: details revised at 1 of 16 entries
Study First Submitted
Notable: the plan changed
Endpoints
Primary
Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)
Timeframe: Baseline up to 28 days
Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)
Timeframe: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 1 (Dose Escalation): Number of participants with laboratory abnormalities
Timeframe: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 2 (Dose Expansion): Objective Response Rate (ORR)
Timeframe: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Secondary (16)
Part 1: Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Part 1 & Part 2: Disease Control Rate (DCR) as per RECIST v1.1
Part 1 & Part 2: Clinical Benefit Rate (CBR) as per RECIST v1.1
Part 1 & Part 2: Duration of Response (DOR) as per RECIST v1.1
Part 1 & Part 2: Progression-Free Survival (PFS) as per RECIST v1.1
Show 11 moreShow less
Part 1 & Part 2: Time to Response (TTR) as per RECIST v1.1
Part 1: Maximum Observed Serum Concentration (Cmax) & Trough Concentration (Ctrough)
Part 1: Time to Reach Maximum Observed Serum Concentration (Tmax)
Part 1: Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration (AUClast)
Part 1: Effect of Food on Cmax
Part 1: Effect of Food on Tmax
Part 1: Effect of Food on AUClast
Part 2 (Dose Expansion): Number of participants with laboratory abnormalities
Part 2 (Dose Expansion): Incidence of Adverse Events (AEs)
Part 2 (Dose Expansion): Pre- and post-dose concentrations of PF-08165784
Part 2: Overall Survival (OS)
Arms and interventions
Part 1 Dose Escalation Cohort 1AExperimental
PF-08165784 monotherapy dose escalation for participants with advanced or metastatic BC at different doses of the study drug
Part 1 Dose Escalation Cohort 1BExperimental
Combination (PF-08165784 + fulvestrant) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug
Part 1 Dose Escalation Cohort 1CExperimental
Combination (PF-08165784 + fulvestrant + atirmociclib) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug
Part 1 Dose Escalation Cohort 1DExperimental
Combination (PF-08165784 + cetuximab) dose escalation for participants with advanced or metastatic CRC at different doses of the study drug
Part 2 Dose Optimization/Expansion Cohort 2AExperimental
Combination (PF-08165784 + letrozole + atirmociclib) dose optimization/expansion for participants with advanced or metastatic BC, at different doses of the study drug